EP
HRMY icon

Edgestream Partners’s Harmony Biosciences HRMY Stock Holding History

Edgestream Partners’s Portfolio HRMY Stock Details HRMY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$6.68M Buy
183,501
+45,371
+33% +$1.43M 0.2% 162
2026
Q1 		$3.87M Buy
138,130
+47,303
+52% +$1.55M 0.13% 310
2025
Q4 		$3.4M Buy
90,827
+77,436
+578% +$2.55M 0.1% 383
2025
Q3 		$369K Buy
+13,391
New +$461K 0.01% 770
2025
Q2 		– Sell
-75,770
Closed -$2.51M – 936
2025
Q1 		$2.51M Buy
+75,770
New +$2.72M 0.09% 426
2024
Q2 		– Sell
-60,281
Closed -$2.02M – 929
2024
Q1 		$2.02M Buy
60,281
+11,336
+23% +$364K 0.1% 335
2023
Q4 		$1.58M Buy
48,945
+31,302
+177% +$874K 0.11% 301
2023
Q3 		$578K Sell
17,643
-31,429
-64% -$1.09M 0.05% 560
2023
Q2 		$1.73M Buy
+49,072
New +$1.69M 0.16% 222

Other funds holding HRMY

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
LSV Asset Management
LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Edgestream Partners's HRMY Position: Q2 2026 in Review

Edgestream Partners increased its Harmony Biosciences (HRMY) stake by 33% in Q2 2026, buying an estimated $1.43M and bringing the position to 183,501 shares worth $6.68M. The position accounts for 0.2% of the portfolio, ranked #162.

Edgestream Partners first reported a position in HRMY in Q2 2023 and has held it in 9 quarters since. 327 funds tracked by Wall St. Rank hold HRMY as of Q2 2026.

  • Edgestream Partners held 183,501 shares of Harmony Biosciences worth $6.68M as of Q2 2026.
  • Edgestream Partners bought 45,371 Harmony Biosciences shares in Q2 2026, an estimated $1.43M.
  • Harmony Biosciences made up 0.2% of Edgestream Partners's portfolio in Q2 2026, its #162 holding.
  • Edgestream Partners first reported a position in Harmony Biosciences in Q2 2023 and has held it in 9 quarters since.
  • 327 funds tracked by Wall St. Rank held Harmony Biosciences as of Q2 2026.

Based on Edgestream Partners's 13F filing for Q2 2026, filed 11 Aug 2026.